{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-133086","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.847913+00:00","generated_at":"2026-06-02T18:00:36.083507+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Annexon presents positive Phase 2 data for ANX007 in GA; plans Phase 3 trials in 2024","bullets":["ANX007 showed 73% relative risk reduction in BCVA 15-letter loss at 12 months in Phase 2 ARCHER trial.","Statistically significant slowing of low luminance visual acuity loss and reduction in photoreceptor loss observed.","No choroidal neovascularization increase and no cases of vasculitis; generally well-tolerated safety profile.","Global pivotal Phase 3 ARCHER II (vs sham) expected mid-2024; Phase 3 ARROW (vs SYFOVRE) expected H2 2024.","Preclinical data show C1q blockade protects photoreceptor synapses and preserves retinal function in GA models."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-133086","json":"https://secwatch.observer/filing/0001193125-24-133086.json","markdown":"https://secwatch.observer/filing/0001193125-24-133086.md","text":"https://secwatch.observer/filing/0001193125-24-133086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000119312524133086/0001193125-24-133086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000119312524133086/d825274d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:00:36.083507+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}